RxDoctor Payments Data

Jamie Nix

Family · Okmulgee, OKNPI 1437814084

Payments from drug & device makers

$894in general payments, 2019–2025

Across 16 payments — averaging $55.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insmed, Inc.$233
  • AbbVie$149
  • Lilly USA, LLC$120
  • Sanofi-aventis U.S. LLC$119
  • Pharmacosmos Therapeutics Inc.$108
  • Pfizer$78
  • plus $87 from 5 others

What the payments were for

  • Food & beverage$894100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$894 in reported general payments places this provider in the 65th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$15,007
Medicare patients
134
Services billed
277

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide67$62,985
EliquisApixaban50$28,448
JardianceEmpagliflozin47$28,199
Spiriva RespimatTiotropium Bromide15$7,518
Tresiba Flextouch U-100Insulin Degludec24$6,453
AlogliptinAlogliptin Benzoate23$3,260
SynthroidLevothyroxine Sodium73$3,053
Wixela InhubFluticasone Propion/Salmeterol15$863
Albuterol Sulfate HfaAlbuterol Sulfate45$773
Atorvastatin Calcium106$529
Metoprolol Succinate92$524
Fluticasone Propionate45$435
Potassium Chloride44$433
Duloxetine Hcl36$420
Rosuvastatin Calcium46$365

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$16$62,98567 claims
PfizerEliquis$78$28,44850 claims
AbbVieSynthroid$149$3,05373 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,026 family providers in Oklahoma.

Other family in Okmulgee

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →